Baqsimi

RSS

glucagon

Authorised
This medicine is authorised for use in the European Union.

Overview

Baqsimi is a medicine used to treat severe hypoglycaemia (very low blood glucose levels) in adults, adolescents, and children aged 4 years or older who have diabetes.

Hypoglycaemia can occur in people with diabetes when treatments to control blood glucose cause the levels of glucose to become too low. In severe cases, it can make patients faint or become unconscious and must therefore be treated immediately.

Baqsimi contains the active substance glucagon.

This EPAR was last updated on 06/02/2020

Authorisation details

Product details
Name
Baqsimi
Agency product number
EMEA/H/C/003848
Active substance
Glucagon
International non-proprietary name (INN) or common name
glucagon
Therapeutic area (MeSH)
Diabetes Mellitus
Anatomical therapeutic chemical (ATC) code
H04AA01
Publication details
Marketing-authorisation holder
Eli Lilly Nederland B.V.
Date of issue of marketing authorisation valid throughout the European Union
16/12/2019
Contact address

Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

Product information

16/12/2019 Baqsimi - EMEA/H/C/003848 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • PANCREATIC HORMONES
  • Glycogenolytic hormones

Therapeutic indication

Baqsimi is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 4 years and over with diabetes mellitus.

Assessment history

How useful was this page?

Add your rating